BioSpace News Archive

NKGen Biotech, Inc., a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapies, announced that it has closed its previously announced business combination with Graf Acquisition Corp. IV, pursuant to which NKGen became a wholly-owned subsidiary of Graf and Graf changed its name to NKGen Biotech, Inc.

DNA Diagnostics Center (DDC), a pioneer in prenatal DNA testing, is thrilled to announce a significant advancement in early gender determination for expectant parents.

Triumvira Immunologics today announced that it will present clinical data from its ongoing Phase I/II study investigating the safety and efficacy of autologous TAC-T cells targeting HER2 in relapsed or refractory solid tumors (TACTIC-2 /NCT04727151) at two upcoming scientific conferences.

Avenge Bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for AVB-001 for treatment of patients with relapsed resistant/refractory ovarian cancer.

Evecxia Therapeutics, Inc., the leader in serotonin synthesis amplification to treat brain disorders, today announced the absence of toxicity findings associated with the co-administration of EVX-101 in conjunction with the first-line antidepressant fluoxetine in nonclinical GLP toxicology studies.

Nucleix Announces Upcoming Presentation of Performance Data from Sightline Study of Lung EpiCheck ® at the American College of Chest Physicians (CHEST) 2023 Annual Meeting.

Nexcella Inc. (“Nexcella”, “Company”, “We” or “Us”) today announced the presentation of updated data from the ongoing Phase 1b/2 NEXICART-1 (NCT04720313) study of its novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201.

Pulse Biosciences, Inc. today announced a collaboration with CardioNXT, to support Pulse Biosciences’ planned nsPFA cardiac catheter first-in-human study focused on the treatment of atrial fibrillation.

Cutera, Inc. is pleased to announce the appointment of Brent Hauser as President, International, effective October 2, 2023.

Allarity Therapeutics, Inc. is pleased to announce that the Company has been invited to give a presentation at Biomarkers Europe 2023.